REFERENCES
  1. Panagiotis Tsikouras, Stefanos Zervoudis, Bachar Manav et al. Cervical cancer: screening, diagnosis and staging. JBUON. 2016;1(2): 320-325
  2. Patrizia Vic, Luciano Mariani, Laura Pizzuti, et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. Journal of Experimental and Clinical Cancer Research. 2014;33:29
  3. Zheng Hu, Ding MA. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217-5236
  4. Panagiotis Tsikouras, Stefanos Zeroudis, Bachar Manav, et al. Cervical cancer: screening, diagnosis and staging. Journal of B. U. ON. 2016;21(2):320-5
  5. Sebastian Wardak. Human Papillomavirus(HPV) and cervical cancer. Med Dosw Mikrobiol. 2016;68(1):73-84
  6. Gregoire Marret, Edith Borcoman, Christophe Le Tourneau. Pembrolizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2019;19(9):871-877
  7. Sudeep Gupta, Amita Maheshwari, Pallavi Parab, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology. 2018; 36(16):1548-1555
  8. Lise M A De Strooper,Johannes Berkhof,Renske D M Steenbergen, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up. International Journal of Cancer. 2018;143(6):1541-1548
  9. Gulden Menderes, Jonathan Black, Carlton L Schwab et al. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Review of Anticancer Therapy. 2016;16(1):83-98
  10. Elisena Franzese, Sara Centonze, Anna Diana, et al. PARP inhibitors in ovarian cancer. Cancer Treatment Reviews. 2019;73:1-9
  11. Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors. Chinese Journal of Lung Cancer. 2019;22(10):605-614
  12. Lauren M Cuevas, Adil I Daud. Immunotherapy for melanoma. Semin Cutan Med Surg. 2018;37(2):127-131
  13. Suzanne L., F. Stephen Hodi, Julie R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine. 2012;366(26):2443-54
  14. Elizabeth K Lee, Panagiotis A Konstantinopoulos. Combined PARP and immune checkpoint inhibition in ovarian cancer. Trends Cancer. 2019;5(9):524-528
  15. Leonie Voorwerk, Maarten Slagter, Hugo M Horlings et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine. 2019;25(6):920-928
  16. Haoran Li, Xiaohua Wu, and Xi Cheng. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27(4):e43
  17. Arlene H Sharpe, Kristen E Pauken. The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology. 2018;18(3):153-167
  18. L Paré , T Pascual , E Seguí , et al. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Annals of Oncology. 2018;29(10):2121-2128
  19. Jacob P. Smeltzer, Jason M. Jones, Steven C. Ziesmer, et al. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular Lymphoma. Clin Cancer Res. 2014;20(11):2862-2872
  20. Heng Lin, Shuang Wei, Elaine M., Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. The Journal of Clinical Investigation. 2018;128:805-815
  21. Zhifang C.,Nannan P.,Rong D.,et al. Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cell. Mediators of Inflammation. 2016;2016:6891482
  22. Loise M. Francisco, Peter T. Sage, Arlene H. Sharp. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews. 2010; 236:219-42
  23. Schoonderwoerd Mark J A, Koops Maaike F M, Angela Ricardo A, et al. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020;26(14):3831-3842
  24. Dickson Adah, Yijun Yang, Quan Liu, et al. Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model. Cell Commun Signal. 2019;17:32
  25. Haiping Wang, Fabien Franco, Ping-Chih Ho. Metabolic regulation of Tregs in cancer: opportunities for immunotherapy. Trends Cancer. 2017;3(8):583-592
  26. Patrick R Adair, Yong Chan Kim, Ai-Hong Zhang, et al. Human Tregs made antigen specific by gene modification: the power to treat autoimmunity and antidrug antibodies with precision. Front Immunology. 2017;8:1117
  27. Shimon Sakaguchi, Tomoyuki Yamaguchi, Takashi Nomura, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87
  28. Ye Shu, Qinghua Hu, Hai Long, et al. Epigenetic variability of CD4+CD25+Tregs contributes to the pathogenesis of autoimmune diseases. Clinical Reviews in Allergy & immunology. 2017;52(2):260-272
  29. Antonio La Cava. Natural Tregs and autoimmunity. Front Biosci.2009;14:333-43
  30. Mehmet Altan, Kelley M. Kidwell, Vasiliki Pelekanou, et al. Association of B7H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer. 2018;4:40
  31. Schalper, K. A. et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin. Cancer Res. 2014;20:2773-2782
  32. Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014;20:5064-5074
  33. Velcheti, V. et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Investing. 2014;94:107-116